Clinical trials: Neoadjuvant Therapy
Neoadjuvant Chemoradiotherapy
Hyperpolarized 13C-MRI and Radiomics in Rectal Cancer
This study is testing new imaging and analysis methods to improve how doctors predict treatment response in rectal cancer patients receiving chemoradiotherapy.
- Trial name
- DNP_RECA (NCT07730541)
- Testing
- Hyperpolarized 13C-MRI (HP 13C-MRI)
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Hepatocellular Carcinoma
Neoadjuvant Radiotherapy for HCC Involving Type I PVTT
The rate of patients with hepatocellular carcinoma (HCC) involving portal vein tumor thrombus (PVTT) is up to 50% in Guangxi province, China. Some of them will receive hepatic resection, especially those with type I or II PVTT.
- Trial name
- NCT04025437
- Testing
- Hepatectomy alone, Neoadjuvant radiotherapy
- Where
- China
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Breast Neoplasms, Breast Cancer
Surgical Outcome of BCS Using ICG-F in Breast Cancer Patients After Preoperative Chemotherapy
Neoadjuvant chemotherapy for advanced breast cancer has led to an increased rate of breast-conserving surgery (BCS) in these patients.
- Trial name
- NCT06780735
- Testing
- The margin-positive rate using the localization technique
- Where
- South Korea
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
HER2-positive Breast Cancer
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast Cancer
This is a prospective, open-label,multicenter Phase II study for evaluating the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus chemotherapy as neoadjuvant treatment in HER2 positive early stage or locally…
- Trial name
- NCT03847818
- Testing
- Pyrotinib+Trastuzumab+Docetaxel+Carboplatin
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Shandong University
Rectal Cancer
Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer
Preoperative chemoradiation leads to increased pelvic control and overall survival, but both distant and local disease control remain problematic in locally advanced rectal cancer patients.
- Trial name
- NCT00113230
- Testing
- Avastin (Bevacizumab, RHUMAB VEGF), Capecitabine, Radiation Therapy
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Early Primary Breast Cancer
KVUS at Neoadjuvant CTx of Breast Cancer
Effect of the contrast-enhanced diagnostic ultrasound during neoadjuvant chemotherapy of breast cancer on the achieved tumor size reduction and tolerability of chemotherapy
- Trial name
- NCT03385200
- Testing
- SonoVue
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- RWTH Aachen University
Triple Negative Breast Cancer, HER2-positive Breast Cancer
Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer
Patients with Her-2 positive and triple negative breast cancer who received neoadjuvant chemotherapy will be included in the study.
- Trial name
- NCT05169853
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Safety of Excision the New Tumor Size
Outcomes of Breast Conservative Surgery for Post Chemotherapy Tumour Size After Response to Neoadjuvant Chemotherapy
Breast cancer is the most common cancer among women. The morbidity and mortality of breast cancer are much higher than those observed with other female cancers (1). The incidence of breast cancer increases with age (2, 3).
- Trial name
- NCT05115279
- Testing
- breast conservative surgery for post chemotherapy tumour size
- Where
- Egypt
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Assiut University
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma
Neoadjuvant durvalumab (MEDI4736) plus docetaxel, oxaliplatin, S-1 (DOS) followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in potentially resectable MMR proficient (pMMR) gastric or gastroesophageal junction (GEJ)…
- Trial name
- NCT04221555
- Testing
- Docetaxel, Oxaliplatin, S-1 and Durvalumab, Durvalumab and Tremelimumab
- Where
- South Korea
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Locally Advanced Cervical Carcinoma
How To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix
1. This strategy might suggest a therapeutic option to preserve ovarian function in young patients among which locally advanced cancer cervix is common.
- Trial name
- NCT04789941
- Testing
- Cis Platinum + Irinotecan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Sintilimab, Lung Cancer
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
primary purpose：Observe the pathological complete response rate (PCR) of postoperative tumor tissue resection and evaluate the safety of the treatment process.
- Conditions
- Sintilimab, Lung Cancer, Anlotinib, Chemotherapy
- Trial name
- NCT05400070
- Testing
- Neoadjuvant therapy 1
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tang-Du Hospital
Low Back Pain
Effects of Core Stabilization Exercises and Myofascial Induction Therapy in Postpartum Low-back Pain
The aim of this study is to determine the combine effects of core stabilization exercises and Myofascial Induction therapy on lumber pain, core endurance and quality of life on postpartum low-back pain.
- Trial name
- NCT07576244
- Testing
- CORE STABILIZATION EXERCISES, MYOFASCIAL INDUCTION THERAPY
- Where
- Pakistan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Riphah International University
Breast Cancer
Minimally Invasive Biopsy Predicting Breast pCR After NAC for Breast Cancer
Neoadjuvant chemotherapy (NAC) is widely used as an efficient breast cancer treatment. Ideally, a pathological complete remission (pCR) can be achieved.
- Trial name
- MIBPBPCR (NCT03789851)
- Testing
- core needle biopsy
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Shandong Cancer Hospital and Institute
Triple Negative Breast Cancer, Immune Checkpoint Inhibitor
LAG3 Expression in Triple Negative Breast Cancer
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
- Trial name
- NCT06259162
- Testing
- LAG-3 expression / immune checkpoint protein expression
- Where
- South Korea
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Mesothelioma
Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma
Objectives: The investigators will test whether combination of chemoimmunotherapy or dual agent immunotherapy alone improves efficacy for patients with MPM.
- Trial name
- NCT05932199
- Testing
- Durvalumab / tremelimumab, Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Gastric Cancer
Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）
This trial is a multi-center, open, single-arm, superior phase II clinical study.
- Trial name
- NCT05113459
- Testing
- Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Guoxin Li
Breast Cancer, Triple Negative Breast Cancer
Metabolic Sodium MRI to Assess Early Response of Breast Cancer to Neoadjuvant Chemotherapy
Neoadjuvant chemotherapy (NACT) is administered to treat invasive breast cancer before surgery. It offers the opportunity to evaluate tumor response to treatment in aggressive disease, and guide additional therapies for patients…
- Trial name
- NCT03750240
- Testing
- Sodium (Na) Magnetic Resonance Imaging (MRI), Dynamic Contrast- Enhanced (DCE) MRI
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Vitamin D Deficiency, Chemotherapy Effect
Vitamin D Can Increase Pathological Response of the Breast Cancer Patients Treated With Neoadjuvant Therapy
The aim of the study is to evaluate the relationship between the vitamin D replacement and pathological response in patients undergoing neoadjuvant therapy according to different molecular sub types.
- Conditions
- Vitamin D Deficiency, Chemotherapy Effect, Pathology
- Trial name
- NCT03986268
- Testing
- Vit D
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Florence Nightingale Hospital, Istanbul
Breast Cancer, Chemotherapy Effect
Comparison of MRI With PET / CT in the Evaluation of Response to Neoadjuvant Therapy Based on the Molecular Subtypes of Breast Cancer
The current study aims to determine the diagnostic accuracy of Magnetic Resonance Imaging (MRI) and Positron Emission Tomography- Computed Tomography (PET-CT) in predicting a pathological response of molecular subtypes of breast…
- Trial name
- NCT04882371
- Testing
- Chemotherapy, Magnetic Resonance Imaging (MRI), Positron emission tomography - Copmputer Tomography (PET-CT)
- Where
- Turkey (Türkiye)
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Cem Ilgin Erol
Breast Cancer, Invasive Breast Carcinoma
Tissue- and Serum-Derived Exosomal microRNAs as Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer
This prospective observational study aims to evaluate whether exosomal microRNA profiles derived from tumor tissue and blood serum are associated with pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in…
- Conditions
- Breast Cancer, Invasive Breast Carcinoma, Exosomal microRNA, Neoadjuvant Chemotherapy Response
- Trial name
- ExoTSS-BC (NCT07500129)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Atlas University